Although the fluoroquinolones are presently used to treat tuberculosis primarily in cases
involving resistance or intolerance to first-line antituberculosis therapy, these drugs are potential …

Tuberculosis continues to be a major cause of morbidity and mortality in the world. The
expansion of tuberculosis control programs has been limited by the lengthy and cumbersome …

The discovery of Streptomyces-produced streptomycin founded the age of tuberculosis therapy.
Despite the subsequent development of a curative regimen for this disease, tuberculosis …

Rationale: Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and
in a mouse model of antituberculosis (TB) chemotherapy, but data regarding its activity in …

Background Availability of an ultra-short-course drug regimen capable of curing patients
with tuberculosis in 2 to 3 mo would significantly improve global control efforts. Because …

In a recent experimental study using the mouse model of tuberculosis, treatment with a
combination of rifampin, moxifloxacin, and pyrazinamide was able to shorten the time to negative …

PA-824 is a nitroimidazo-oxazine in clinical testing for the treatment of tuberculosis. We report
that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more …

The Mycobacterium tuberculosis dosR gene (Rv3133c) is part of an operon, Rv3134c-Rv3132c,
and encodes a response regulator that has been shown to be upregulated by hypoxia …

In previous experiments, replacing the 10-mg/kg of body weight daily dose of rifampin with 7.5
to 10 mg/kg of rifapentine in combinations containing isoniazid and pyrazinamide reduced …

The objective of this review is to report evidence about the efficacy and potential of currently
licensed drugs and new molecules beyond pre-clinical development for improving the …